

Darrell Pardi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7382182/publications.pdf>

Version: 2024-02-01

222
papers

11,516
citations

23500
58
h-index

33814
99
g-index

228
all docs

228
docs citations

228
times ranked

8807
citing authors

#	ARTICLE	IF	CITATIONS
1	Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. <i>Gastroenterology</i> , 2003, 124, 889-893.	0.6	534
2	The Epidemiology of Community-Acquired <i>Clostridium difficile</i> Infection: A Population-Based Study. <i>American Journal of Gastroenterology</i> , 2012, 107, 89-95.	0.2	518
3	Prospective Comparison of State-of-the-Art MR Enterography and CT Enterography in Small-Bowel Crohn's Disease. <i>American Journal of Roentgenology</i> , 2009, 193, 113-121.	1.0	357
4	Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. <i>Gastrointestinal Endoscopy</i> , 2008, 68, 255-266.	0.5	333
5	A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent <i>Clostridium difficile</i> Infection. <i>Journal of Infectious Diseases</i> , 2016, 214, 173-181.	1.9	277
6	Administration of Spores of Nontoxigenic <i>Clostridium difficile</i> Strain M3 for Prevention of Recurrent <i>C difficile</i> Infection. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1719.	3.8	270
7	Review article: drug-induced microscopic colitis - proposal for a scoring system and review of the literature. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 277-284.	1.9	256
8	The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. <i>Gut</i> , 2007, 56, 504-508.	6.1	223
9	High-Dose Ursodeoxycholic Acid Is Associated With the Development of Colorectal Neoplasia in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis. <i>American Journal of Gastroenterology</i> , 2011, 106, 1638-1645.	0.2	223
10	Adult Autoimmune Enteropathy: Mayo Clinic Rochester Experience. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1282-1290.	2.4	220
11	Risk of Cerebrovascular Accidents and Ischemic Heart Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 382-393.e1.	2.4	218
12	Microscopic Colitis. <i>Gastroenterology</i> , 2011, 140, 1155-1165.	0.6	213
13	Diagnostic Ionizing Radiation Exposure in a Population-Based Cohort of Patients with Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2008, 103, 2015-2022.	0.2	184
14	The Epidemiology of <i>Clostridium difficile</i> Infection in Children: A Population-Based Study. <i>Clinical Infectious Diseases</i> , 2013, 56, 1401-1406.	2.9	182
15	Inflammatory Bowel Disease Is Associated With an Increased Risk of Melanoma: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 210-218.	2.4	169
16	Chronic Diarrhea: Diagnosis and Management. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 182-193.e3.	2.4	149
17	Lymphocytic colitis: clinical features, treatment, and outcomes. <i>American Journal of Gastroenterology</i> , 2002, 97, 2829-2833.	0.2	148
18	Symptomatic overlap between irritable bowel syndrome and microscopic colitis. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 175-181.	0.9	146

#	ARTICLE	IF	CITATIONS
19	Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurine. <i>Gastroenterology</i> , 2001, 120, 1483-1484.	0.6	145
20	The growing incidence and severity of <i>Clostridium difficile</i> infection in inpatient and outpatient settings. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010, 4, 409-416.	1.4	142
21	Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent <i>Clostridium difficile</i> Infection: Results of the PUNCH CD Study. <i>Clinical Infectious Diseases</i> , 2016, 62, 596-602.	2.9	140
22	Low Cure Rates in Controlled Trials of Fecal Microbiota Transplantation for Recurrent <i>Clostridium difficile</i> Infection: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2019, 68, 1351-1358.	2.9	137
23	<i>Clostridioides difficile</i> uses amino acids associated with gut microbial dysbiosis in a subset of patients with diarrhea. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	128
24	Validation of the Ulcerative Colitis Colonoscopic Index of Severity and Its Correlation With Disease Activity Measures. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 49-54.e1.	2.4	126
25	Microscopic colitis: a review. <i>American Journal of Gastroenterology</i> , 2002, 97, 794-802.	0.2	125
26	Association of Gastric Acid Suppression With Recurrent <i>Clostridium difficile</i> Infection. <i>JAMA Internal Medicine</i> , 2017, 177, 784.	2.6	120
27	Changes in microbial ecology after fecal microbiota transplantation for recurrent <i>C. difficile</i> infection affected by underlying inflammatory bowel disease. <i>Microbiome</i> , 2017, 5, 55.	4.9	118
28	<i>Clostridium difficile</i> Infection: New Insights Into Management. <i>Mayo Clinic Proceedings</i> , 2012, 87, 1106-1117.	1.4	117
29	Diagnosis and Management of Microscopic Colitis. <i>American Journal of Gastroenterology</i> , 2017, 112, 78-85.	0.2	117
30	Colonic ulcers accompanying collagenous colitis: implication of nonsteroidal anti-inflammatory drugs. <i>American Journal of Gastroenterology</i> , 2003, 98, 1834-1837.	0.2	114
31	Autoimmune Enteropathy: A Review and Update of Clinical Management. <i>Current Gastroenterology Reports</i> , 2012, 14, 380-385.	1.1	112
32	Clinical guidelines for the management of pouchitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1424-1431.	0.9	111
33	Fecal Microbiota Transplantation for Recurrent <i>Clostridium difficile</i> Infection Reduces Recurrent Urinary Tract Infection Frequency. <i>Clinical Infectious Diseases</i> , 2017, 65, 1745-1747.	2.9	110
34	Systematic review: the management of pouchitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 1087-1096.	1.9	104
35	Inflammatory Bowel Disease of the Elderly: Frequently Asked Questions (FAQs). <i>American Journal of Gastroenterology</i> , 2011, 106, 1889-1897.	0.2	104
36	Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. <i>The Cochrane Library</i> , 2015, , CD001176.	1.5	99

#	ARTICLE	IF	CITATIONS
37	The Epidemiology of Microscopic Colitis in Olmsted County From 2002 to 2010: A Population-Based Study. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 838-842.	2.4	98
38	Comparative Efficacy of Pharmacologic Interventions in Preventing Relapse of Crohn's Disease After Surgery: A Systematic Review and Network Meta-analysis. <i>Gastroenterology</i> , 2015, 148, 64-76.e2.	0.6	97
39	SER-109, an Investigational Microbiome Drug to Reduce Recurrence After <i>Clostridioides difficile</i> Infection: Lessons Learned From a Phase 2 Trial. <i>Clinical Infectious Diseases</i> , 2021, 72, 2132-2140.	2.9	96
40	Prevalence and Mortality of COVID-19 Patients With Gastrointestinal Symptoms: A Systematic Review and Meta-analysis. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1632-1648.	1.4	95
41	Gut microbiome predictors of treatment response and recurrence in primary <i>Clostridium difficile</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 715-727.	1.9	94
42	High risk of post-infectious irritable bowel syndrome in patients with <i>Clostridium difficile</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 576-582.	1.9	89
43	Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. , 2010, , CD001176.		87
44	Increased Risk of Acute Myocardial Infarction and Heart Failure in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1607-1615.e1.	2.4	87
45	Epidemiology, risk factors and management of cardiovascular diseases in IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 26-35.	8.2	82
46	Gastro 2013 APDW/WCOG Shanghai Working Party Report: Chronic diarrhea: Definition, classification, diagnosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 6-25.	1.4	77
47	Outcomes in community-acquired <i>Clostridium difficile</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 613-618.	1.9	71
48	<i>Clostridium difficile</i> Infection in Patients With Chronic Kidney Disease. <i>Mayo Clinic Proceedings</i> , 2012, 87, 1046-1053.	1.4	70
49	Comparative Efficacy of Biologic Therapy in Biologic-Naïve Patients With Crohn Disease: A Systematic Review and Network Meta-analysis. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1621-1635.	1.4	70
50	Paraneoplastic Dysmotility: Loss of Interstitial Cells of Cajal. <i>American Journal of Gastroenterology</i> , 2002, 97, 1828-1833.	0.2	69
51	Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 826-849.	3.7	69
52	Effect of Ursodeoxycholic Acid Use on the Risk of Colorectal Neoplasia in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1631-1638.	0.9	68
53	Microscopic Colitis. <i>Inflammatory Bowel Diseases</i> , 2004, 10, 860-870.	0.9	67
54	Benefit of Computed Tomography Enterography in Crohn's Disease: Effects on Patient Management and Physician Level of Confidence. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 219-225.	0.9	66

#	ARTICLE	IF	CITATIONS
55	Cytomegalovirus Infection of the Ileoanal Pouch. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2394-2399.	0.9	66
56	Faecal microbiota transplantation for eradicating carriage of multidrug-resistant organisms: a systematic review. <i>Clinical Microbiology and Infection</i> , 2019, 25, 958-963.	2.8	66
57	Outcomes of Patients With Microscopic Colitis Treated With Corticosteroids: A Population-Based Study. <i>American Journal of Gastroenterology</i> , 2013, 108, 256-259.	0.2	62
58	Role of interventional inflammatory bowel disease in the era of biologic therapy: a position statement from the Global Interventional IBD Group. <i>Gastrointestinal Endoscopy</i> , 2019, 89, 215-237.	0.5	61
59	Clostridium difficile-Associated Diarrhea and Colitis. <i>Mayo Clinic Proceedings</i> , 2001, 76, 725-730.	1.4	60
60	Gastric Acid Suppression and Outcomes in Clostridium difficile Infection: A Population-Based Study. <i>Mayo Clinic Proceedings</i> , 2012, 87, 636-642.	1.4	60
61	Clinical Factors Associated With Development of Severe-Complicated Clostridium difficile Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1466-1471.	2.4	60
62	Long-term Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. <i>Gastroenterology</i> , 2021, 160, 1961-1969.e3.	0.6	59
63	Review of the Microscopic Colitides. <i>Current Gastroenterology Reports</i> , 2011, 13, 458-464.	1.1	58
64	Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 616-617.	2.4	58
65	Clinical management of pouchitis. <i>Gastroenterology</i> , 2004, 127, 1809-1814.	0.6	57
66	Safety and Efficacy of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Patients With Cancer Treated With Cytotoxic Chemotherapy: A Single-Institution Retrospective Case Series. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1617-1624.	1.4	53
67	Low Risk of Primary Clostridium difficile Infection With Tetracyclines: A Systematic Review and Metaanalysis. <i>Clinical Infectious Diseases</i> , 2018, 66, 514-522.	2.9	51
68	Donor Screening Experience for Fecal Microbiota Transplantation in Patients With Recurrent C. difficile Infection. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 146-150.	1.1	50
69	Budesonide in the treatment of inflammatory bowel disease: The first year of experience in clinical practice. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 29-32.	0.9	49
70	Validation of a CT-Derived Method for Osteoporosis Screening in IBD Patients Undergoing Contrast-Enhanced CT Enterography. <i>American Journal of Gastroenterology</i> , 2014, 109, 401-408.	0.2	49
71	Symptomatic Overlap Between Microscopic Colitis and Irritable Bowel Syndrome. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 550-553.	0.9	48
72	Adalimumab for Crohn's disease in clinical practice at Mayo clinic: The first 118 patients. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1912-1921.	0.9	45

#	ARTICLE	IF	CITATIONS
73	Measurement of disease activity in ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1257-1264.	0.9	45
74	Observer variability in the histologic diagnosis of microscopic colitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 35-38.	0.9	44
75	Review article: microscopic colitis - lymphocytic, collagenous and "mast cell" colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 21-32.	1.9	43
76	Meta-analysis: serological markers and the risk of acute and chronic pouchitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 867-875.	1.9	42
77	Increasing antibiotic resistance in <i>Clostridioides difficile</i> : A systematic review and meta-analysis. <i>Anaerobe</i> , 2019, 58, 35-46.	1.0	41
78	Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 69-95.	3.7	41
79	Assessment of appropriateness of indications for CT enterography in younger patients. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 226-232.	0.9	39
80	Incremental diagnostic yield of chromoendoscopy and outcomes in inflammatory bowel disease patients with a history of colorectal dysplasia on white-light endoscopy. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 1005-1012.	0.5	39
81	Immune modulator therapy for microscopic colitis in a case series of 73 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 169-174.	1.9	39
82	<i>Clostridium difficile</i> infection: management strategies for a difficult disease. <i>Therapeutic Advances in Gastroenterology</i> , 2014, 7, 72-86.	1.4	38
83	Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers?. <i>Gut</i> , 2005, 54, 321-322.	6.1	37
84	Epidemiology, outcomes, and predictors of mortality in hospitalized adults with <i>Clostridium difficile</i> infection. <i>Internal and Emergency Medicine</i> , 2016, 11, 657-665.	1.0	37
85	An Evaluation of Repeat Stool Testing for <i>Clostridium difficile</i> Infection by Polymerase Chain Reaction. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 846-849.	1.1	35
86	Outcomes With Fidaxomicin Therapy in <i>Clostridium difficile</i> Infection. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 151-154.	1.1	35
87	Poor outcomes after <i>Clostridium difficile</i> infection in IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 307-308.	8.2	34
88	Natalizumab for moderate to severe Crohn's disease in clinical practice: The Mayo Clinic Rochester experience. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2203-2208.	0.9	34
89	Extraintestinal <i>Clostridium difficile</i> Infections: A Single-Center Experience. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1525-1536.	1.4	34
90	Update on Anti-Tumor Necrosis Factor Agents in Crohn Disease. <i>Gastroenterology Clinics of North America</i> , 2014, 43, 457-478.	1.0	34

#	ARTICLE	IF	CITATIONS
91	Fecal microbiota transplantation for gastrointestinal disorders. <i>Current Opinion in Gastroenterology</i> , 2017, 33, 8-13.	1.0	34
92	Influence of Malpractice History on the Practice of Screening and Surveillance for Barrett's Esophagus. <i>American Journal of Gastroenterology</i> , 2008, 103, 842-849.	0.2	33
93	Editorial: additional evidence for drug-induced microscopic colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1343-1344.	1.9	33
94	Development of a Microscopic Colitis Disease Activity Index: a prospective cohort study. <i>Gut</i> , 2018, 67, 441-446.	6.1	33
95	Early measles virus infection is associated with the development of inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2000, 95, 1480-1485.	0.2	32
96	American Gastroenterological Association Institute Technical Review on the Medical Management of Microscopic Colitis. <i>Gastroenterology</i> , 2016, 150, 247-274.e11.	0.6	32
97	Treatment of Inflammatory Bowel Disease in the Elderly. <i>Drugs and Aging</i> , 2002, 19, 355-363.	1.3	31
98	The Efficacy and Tolerability of AST-120 (Spherical Carbon Adsorbent) in Active Pouchitis. <i>American Journal of Gastroenterology</i> , 2009, 104, 1468-1474.	0.2	31
99	Inflammatory Bowel Disease in the Elderly. <i>Drugs and Aging</i> , 2010, 27, 617-624.	1.3	31
100	Low Risk of Pneumonia From <i>Pneumocystis jirovecii</i> Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 850-856.	2.4	31
101	Clinical Benefit of Capsule Endoscopy in Crohn's Disease: Impact on Patient Management and Prevalence of Proximal Small Bowel Involvement. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1582-1588.	0.9	31
102	Efficacy of Fecal Microbiota Transplantation for Recurrent <i>C. Difficile</i> Infection in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1415-1420.	0.9	31
103	Collagenous Colitis Is Associated With HLA Signature and Shares Genetic Risks With Other Immune-Mediated Diseases. <i>Gastroenterology</i> , 2020, 159, 549-561.e8.	0.6	31
104	Update on Treatment of <i>Clostridioides difficile</i> Infection. <i>Mayo Clinic Proceedings</i> , 2020, 95, 758-769.	1.4	31
105	Endoscopy in the management of patients after ileal pouch surgery for ulcerative colitis. <i>Endoscopy</i> , 2008, 40, 529-533.	1.0	30
106	Clinical implications of antibiotic impact on gastrointestinal microbiota and <i>Clostridium difficile</i> infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1145-1152.	1.4	30
107	Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. <i>Gastrointestinal Endoscopy</i> , 2018, 88, 360-369.e2.	0.5	29
108	Knowledge of Hepatocellular Carcinoma Screening Guidelines and Clinical Practices Among Gastroenterologists. <i>Digestive Diseases and Sciences</i> , 2011, 56, 569-577.	1.1	27

#	ARTICLE	IF	CITATIONS
109	RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients'™ Microbiomes in a Phase 1 Study for Recurrent <i>Clostridioides difficile</i> Infections. <i>Clinical Infectious Diseases</i> , 2021, 73, e1613-e1620.	2.9	27
110	Fecal Microbiota Transplantation for Recurrent <i>Clostridioides difficile</i> infection: The COVID-19 Era. <i>American Journal of Gastroenterology</i> , 2020, 115, 971-974.	0.2	27
111	Clinical predictors of recurrent <i>Clostridium difficile</i> infection in outpatients. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 518-522.	1.9	26
112	Microscopic colitis. <i>Nature Reviews Disease Primers</i> , 2021, 7, 39.	18.1	26
113	New-Onset Microscopic Colitis in an Ulcerative Colitis Patient After Fecal Microbiota Transplantation. <i>American Journal of Gastroenterology</i> , 2016, 111, 751-752.	0.2	25
114	Optimization of a Scoring System to Predict Microscopic Colitis in a Cohort of Patients With Chronic Diarrhea. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 228-234.	1.1	25
115	Management of the Elderly Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2257-2272.	0.9	24
116	Non- <i>Clostridium difficile</i> Bacterial Infections Are Rare in Patients With Flares of Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 528-533.	2.4	23
117	T1193 A Randomized, Double-Blind, Placebo-Controlled Trial of Budesonide for the Treatment of Active Lymphocytic Colitis. <i>Gastroenterology</i> , 2009, 136, A-519-A-520.	0.6	22
118	Trends in the Incidence and Outcomes of Hospitalized Cancer Patients With <i>Clostridium difficile</i> Infection: A Nationwide Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 466-472.	2.3	22
119	Predictors of failure after fecal microbiota transplantation for recurrent <i>Clostridioides difficile</i> infection: a systematic review and meta-analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1383-1392.	1.3	22
120	After budesonide, what next for collagenous colitis?. <i>Gut</i> , 2009, 58, 3-4.	6.1	21
121	The incidence and outcomes from <i>Clostridium difficile</i> infection in hospitalized adults with inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1240-1247.	0.6	20
122	Outcomes in Patients with SARS-CoV-2 and <i>Clostridioides difficile</i> Coinfection. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 1645-1648.	1.1	20
123	Microscopic colitis is not associated with cholecystectomy or appendectomy. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 708-711.	0.9	19
124	The Epidemiology of Microscopic Colitis in Olmsted County, Minnesota: Population-Based Study From 2011 to 2019. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1085-1094.	2.4	19
125	"Community-Acquired <i>Clostridium difficile</i> Infection: An Emerging Entity". <i>Clinical Infectious Diseases</i> , 2012, 55, 1741-1742.	2.9	18
126	Acute Kidney Injury is an Independent Marker of Severity in <i>Clostridium difficile</i> Infection. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 481-484.	1.1	18

#	ARTICLE	IF	CITATIONS
127	Screening for Clostridium difficile colonization on admission to a hematopoietic stem cell transplant unit may reduce hospital-acquired C difficile infection. American Journal of Infection Control, 2018, 46, 459-461.	1.1	18
128	Predictors and Management of Failed Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. Journal of Clinical Gastroenterology, 2021, 55, 542-547.	1.1	18
129	Perinatal Exposure to Measles Virus Is Not Associated with the Development of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 1999, 5, 104-106.	0.9	17
130	Microscopic Colitis. Mayo Clinic Proceedings, 2003, 78, 614-617.	1.4	17
131	The fate of indefinite and low-grade dysplasia in ulcerative colitis and primary sclerosing cholangitis colitis before and after liver transplantation. Alimentary Pharmacology and Therapeutics, 2013, 38, 977-987.	1.9	17
132	Current Approach to the Evaluation and Management of Microscopic Colitis. Current Gastroenterology Reports, 2017, 19, 8.	1.1	17
133	Experience and Outcomes at a Specialized Clostridium difficile Clinical Practice. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2017, 1, 49-56.	1.2	17
134	Medication use and microscopic colitis: a multicentre retrospective cohort study. Alimentary Pharmacology and Therapeutics, 2021, 53, 1209-1215.	1.9	17
135	Should the National GI Fellowship Matching Program Be Restored?. American Journal of Gastroenterology, 2004, 99, 1411-1412.	0.2	16
136	Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. The Cochrane Library, 2019, 5, CD001176.	1.5	16
137	Non-IBD colitides (eosinophilic, microscopic). Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012, 26, 611-622.	1.0	15
138	Clinical Activity and Quality of Life Indices Are Valid Across Ulcerative Colitis But Not Crohn's Disease Phenotypes. Digestive Diseases and Sciences, 2016, 61, 2627-2635.	1.1	15
139	Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. The Cochrane Library, 2019, 11, CD001176.	1.5	15
140	Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection. Inflammatory Bowel Diseases, 2019, 25, 610-619.	0.9	15
141	Microscopic Colitis: A Concise Review for Clinicians. Mayo Clinic Proceedings, 2021, 96, 1302-1308.	1.4	14
142	Clinical Features and Treatment Responses in Pediatric Lymphocytic and Collagenous Colitis. Journal of Pediatric Gastroenterology and Nutrition, 2013, 57, 557-561.	0.9	13
143	Outcomes in children with Clostridium difficile infection: results from a nationwide survey. Gastroenterology Report, 2016, 4, gow007.	0.6	13
144	An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials. Alimentary Pharmacology and Therapeutics, 2021, 53, 1108-1117.	1.9	13

#	ARTICLE	IF	CITATIONS
145	Appendectomy Is Not Associated With Adverse Outcomes in Clostridium difficile Infection: A Population-Based Study. American Journal of Gastroenterology, 2013, 108, 626-627.	0.2	12
146	Microscopic Colitis. Clinics in Geriatric Medicine, 2014, 30, 55-65.	1.0	12
147	Efficacy of oral vancomycin prophylaxis for prevention of Clostridioides difficile infection: a systematic review and meta-analysis. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482199404.	1.4	12
148	Budesonide Maintenance in Microscopic Colitis: Clinical Outcomes and Safety Profile From a Population-Based Study. American Journal of Gastroenterology, 2022, 117, 1311-1315.	0.2	12
149	Composition, diversity and potential utility of intervention-naïve pancreatic cancer intratumoral microbiome signature profiling via endoscopic ultrasound. Gut, 2022, 71, 441-443.	6.1	11
150	Fecal Microbiota Transplantation for Recurrent C difficile Infection During the COVID-19 Pandemic. Mayo Clinic Proceedings, 2021, 96, 1418-1425.	1.4	11
151	841 The Natural History of Microscopic Colitis Treated with Corticosteroids. Gastroenterology, 2008, 134, A-121-A-122.	0.6	10
152	413 Age is not Associated With Adverse Events From Biologic Therapy in Patients With Inflammatory Bowel Disease. Gastroenterology, 2010, 138, S-62.	0.6	10
153	Outcomes from Rectal Vancomycin Therapy in Patients With Clostridium difficile Infection. American Journal of Gastroenterology, 2014, 109, 924-925.	0.2	10
154	Clostridium difficile infection after restorative proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis. Colorectal Disease, 2016, 18, O154-7.	0.7	10
155	The Combination of Patient-Reported Clinical Symptoms and an Endoscopic Score Correlates Well with Health-Related Quality of Life in Patients with Ulcerative Colitis. Journal of Clinical Medicine, 2019, 8, 1171.	1.0	10
156	Miscellaneous colitides. Current Opinion in Gastroenterology, 2012, 28, 76-81.	1.0	9
157	Mo1116 The Efficacy and Safety of Rifaximin vs. Vancomycin in the Treatment of Mild to Moderate C. difficile Infection: A Randomized Double-Blind Active Comparator Trial. Gastroenterology, 2012, 142, S-599.	0.6	8
158	Comparative Outcomes of Younger and Older Hospitalized Patients with Inflammatory Bowel Disease Treated with Corticosteroids. Inflammatory Bowel Diseases, 2013, 19, 2644-2651.	0.9	8
159	Durability of Response to Fecal Microbiota Transplantation After Exposure to Risk Factors for Recurrence in Patients With Clostridioides difficile Infection. Clinical Infectious Diseases, 2021, 73, e1706-e1712.	2.9	8
160	Recurrent Clostridium Difficile Infection: An Immunodeficiency State?. Clinical Gastroenterology and Hepatology, 2007, 5, 672-673.	2.4	7
161	S1211 Clinical Benefit of CT Enterography in Suspected or Established Crohn's Disease: Impact On Patient Management and Physician Level of Confidence. Gastroenterology, 2008, 134, A-202.	0.6	7
162	Patients With Drug-Induced Microscopic Colitis Should Not Be Included in Controlled Trials Assessing the Efficacy of Anti-Inflammatory Drugs in Microscopic Colitis. Gastroenterology, 2009, 137, 1535-1536.	0.6	7

#	ARTICLE	IF	CITATIONS
163	Gastric Acid Suppression and Clostridium difficile Infection: Is There a Causal Connection?. Clinical Gastroenterology and Hepatology, 2012, 10, 564.	2.4	7
164	Validation of a Scoring System to Predict Microscopic Colitis in a Cohort of Patients With Chronic Diarrhea. Clinical Gastroenterology and Hepatology, 2016, 14, 777-778.	2.4	7
165	The surgical management of inflammatory bowel disease. Current Problems in Surgery, 2017, 54, 172-250.	0.6	7
166	Statin use and the risk of Clostridium difficile infection: a systematic review with meta-analysis. Infection and Drug Resistance, 2018, Volume 11, 405-416.	1.1	7
167	Clostridium difficile Infection in the Emergency Department. Journal of Clinical Gastroenterology, 2020, 54, 350-355.	1.1	7
168	Systematic Review and Meta-Analysis: Efficacy of Vancomycin Taper and Pulse Regimens in Clostridioides difficile Infection. Expert Review of Anti-Infective Therapy, 2022, 20, 577-583.	2.0	7
169	Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium. The Lancet Gastroenterology and Hepatology, 2022, 7, 871-893.	3.7	7
170	Inflammatory bowel disease in the elderly. Aging Health, 2007, 3, 77-84.	0.3	6
171	A 1-Year Cross-sectional Inflammatory Bowel Disease Surveillance Colonoscopy Cohort Comparing High-definition White Light Endoscopy and Chromoendoscopy. Inflammatory Bowel Diseases, 2021, 27, 594-602.	0.9	6
172	Novel risk factors and outcomes in inflammatory bowel disease patients with Clostridioides difficile infection. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482199779.	1.4	6
173	Su1353 Outcomes of Patients With Microscopic Colitis Treated With Bismuth Subsalicylate. Gastroenterology, 2015, 148, S-483.	0.6	5
174	Extended-release Multimatrix Budesonide for Microscopic Colitis. Inflammatory Bowel Diseases, 2017, 23, E21-E22.	0.9	5
175	Use of Anti-Tumor Necrosis Factors and Anti-Integrins in the Treatment of Crohn's Disease. Gastroenterology Clinics of North America, 2017, 46, 589-601.	1.0	5
176	Presence of immune deficiency increases the risk of hospitalization in patients with norovirus infection. Diagnostic Microbiology and Infectious Disease, 2018, 90, 300-306.	0.8	5
177	Vulvar Crohn's Disease: Clinical Features and Outcomes. American Journal of Gastroenterology, 2021, 116, 2296-2299.	0.2	5
178	Treatment outcomes in lymphocytic colitis. Gastroenterology, 2001, 120, A13.	0.6	4
179	Tu1381 Genome-Wide Association Identifies Multiple Collagenous Colitis Susceptibility Loci. Gastroenterology, 2015, 148, S-875.	0.6	4
180	Outcomes in Patients with Recurrent Clostridium Difficile Infection Treated with Vancomycin Taper. Gastroenterology, 2017, 152, S348.	0.6	4

#	ARTICLE	IF	CITATIONS
181	In Search of the (Clostridium difficile) Holy Grail. Clinical Infectious Diseases, 2019, 70, 1094-1095.	2.9	4
182	Microscopic Colitis and Risk of Colon Adenomas: A Multicenter Retrospective Cohort Study. Clinical Gastroenterology and Hepatology, 2022, 20, e902-e904.	2.4	4
183	Clinical Characteristics and Treatment Response in Microscopic Colitis Based on Age at Diagnosis: A Multicenter Retrospective Study. Digestive Diseases and Sciences, 2021, , 1.	1.1	4
184	Fecal microbiota transplant via colonoscopy may be preferred due to intraprocedure findings. Intestinal Research, 2019, 17, 434-437.	1.0	4
185	Re: Kreiss et al.: pneumatosis intestinalis complicating C. difficile pseudomembranous colitis. American Journal of Gastroenterology, 2000, 95, 1107-1107.	0.2	2
186	Utility of symptom-based criteria for evaluating patients with chronic diarrhea. Gastrointestinal Endoscopy, 2005, 62, 649.	0.5	2
187	Predicting Microscopic Colitis Before Colon Biopsies: A Look Into the Crystal Ball?. Clinical Gastroenterology and Hepatology, 2015, 13, 1132-1133.	2.4	2
188	990 Cumulative Probability and Outcomes of Anti-Tumor Necrosis Factor Use in Patients With Crohn's Disease: A Population-Based Study. Gastroenterology, 2016, 150, S202-S203.	0.6	2
189	Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360, 2019, 1, .	0.5	2
190	Development of Gastroenterology and Transplant Hepatology Milestones 2.0: A Guide For Programs, Faculty, and Fellows. Hepatology, 2021, 74, 2226-2232.	3.6	2
191	Comparison Between Community Acquired and Hospital Acquired Clostridium difficile Infection: A Population-based Study. American Journal of Gastroenterology, 2009, 104, S183.	0.2	2
192	Clinical Course and Impact of Immune Checkpoint Inhibitor Colitis Resembling Microscopic Colitis. Crohn's & Colitis 360, 2022, 4, .	0.5	2
193	Microscopic Colitis. Frontiers of Gastrointestinal Research, 2009, , 135-145.	0.1	1
194	Case report. Medicine (United States), 2017, 96, e8355.	0.4	1
195	The Incidence of Colonic Neoplasia in Patients With Microscopic Colitis and Chronic Diarrhea: A Retrospective Case Control Study. American Journal of Gastroenterology, 2018, 113, S107.	0.2	1
196	Reply to Khoruts and Sadowsky. Clinical Infectious Diseases, 2019, 69, 2233-2234.	2.9	1
197	844 MEDICATION USE AND MICROSCOPIC COLITIS: A MULTICENTER RETROSPECTIVE COHORT STUDY. Gastroenterology, 2020, 158, S-170.	0.6	1
198	Incidence of Clostridioides difficile infection in peripartum women: a retrospective cohort study. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482094262.	1.4	1

#	ARTICLE	IF	CITATIONS
199	Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience. <i>Crohn's & Colitis</i> 360, 2021, 3, .	0.5	1
200	Letter: safety of immune checkpoint inhibitors in patients with pre-established microscopic colitis—a single-centre experience. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 217-218.	1.9	1
201	Development of gastroenterology and transplant hepatology milestones 2.0: a guide for programs, faculty, and fellows. <i>American Journal of Gastroenterology</i> , 2021, Publish Ahead of Print, 2009-2013.	0.2	1
202	Clinical Features and Outcomes of Cytomegalovirus Colitis or Pouchitis in Patients with Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2005, 100, S316.	0.2	1
203	Donor Screening Experience for Fecal Microbiota Transplantation for Patients with Recurrent <i>C. difficile</i> Infection. <i>American Journal of Gastroenterology</i> , 2016, 111, S458.	0.2	1
204	Editorial: autoimmune diseases in microscopic colitis—how does this information help clinicians?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1357-1358.	1.9	1
205	Microscopic colitis and disease associations: authors'™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 820-821.	1.9	0
206	1620Extraintestinal <i>Clostridium difficile</i> infections: A Single Center Experience. <i>Open Forum Infectious Diseases</i> , 2014, 1, S433-S433.	0.4	0
207	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 2135.	2.4	0
208	Letter: clinical predictors of <i>Clostridium difficile</i> infection — advanced age and residential status are important factors for prediction and prevention — authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 233-233.	1.9	0
209	Letter: the definition of budesonide dependence in microscopic colitis—authors'™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 636-636.	1.9	0
210	Tetracyclines are Associated with a Reduced Risk of <i>Clostridium difficile</i> Infection: A Systematic Review and Meta-analysis. <i>Open Forum Infectious Diseases</i> , 2017, 4, S384-S384.	0.4	0
211	Reply to Davido et al. <i>Clinical Infectious Diseases</i> , 2018, 66, 483-485.	2.9	0
212	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 572.	2.4	0
213	Microscopic Colitis, Collagenous and Lymphocytic. , 2020, , 567-574.		0
214	Reply to Lagier et al. <i>Clinical Infectious Diseases</i> , 2020, 70, 2454-2455.	2.9	0
215	Response to —Comments on the published systematic review and meta-analysis on the increasing antibiotic resistance in <i>Clostridioides difficile</i> —™ by Kouhsari et al.. <i>Anaerobe</i> , 2020, 61, 102148.	1.0	0
216	Development of gastroenterology and transplant hepatology milestones 2.0: a guide for programs, faculty, and fellows. <i>Gastrointestinal Endoscopy</i> , 2021, 94, 665-670.	0.5	0

#	ARTICLE	IF	CITATIONS
217	Development of Gastroenterology and Transplant Hepatology Milestones 2.0: A Guide for Programs, Faculty, and Fellows. <i>Gastroenterology</i> , 2021, 161, 1318-1324.	0.6	0
218	Reply. <i>Gastroenterology</i> , 2021, 161, 1345.	0.6	0
219	Kinetics of polymerase chain reaction positivity in patients with <i>Clostridioides difficile</i> infection. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110504.	1.4	0
220	Microscopic Colitis. , 2010, , 93-103.		0
221	Safety and Efficacy of Fecal Microbiota Transplantation for Recurrent <i>Clostridium</i> Infection in Patients with Hematologic Malignancies. <i>Blood</i> , 2016, 128, 3599-3599.	0.6	0
222	Abnormal findings on abdominopelvic cross-sectional imaging in patients with microscopic colitis: a retrospective, multicenter study. <i>Scandinavian Journal of Gastroenterology</i> , 2021, , 1-7.	0.6	0